Forecast

There is no analyst data available for this company.

News Go to news feed

Novacyt achieves 18% revenue growth in first half of 2026

Novacyt reports H1 2026 revenue of £11.6m, an increase of 18% year on year. The instruments segment grew around 30% thanks to the LightBench Discover platform, while the clinical business rose by more than 20% driven by demand for non‑invasive prenatal tests and products for treating sickle cell disease. The acquisition of Southern Cross Diagnostics contributed £1.8m post‑acquisition; sales increased by over 30% in the Americas and by about 22% in Asia-Pacific. Novacyt is implementing a restructuring programme expected to deliver up to £4.0m in annual cost savings and anticipates IVDR approval for the DPYD kit in the coming months. » More on de.investing.com
Novacyt publishes annual report and financial statements for 2025

Novacyt has published its annual report and financial statements for the year ended 31 December 2025 and made them available on the company website. The company, which specializes in molecular diagnostics, reports on its three business divisions—clinical diagnostics, instrumentation and research use only—and highlights its global presence in more than 65 countries. Novacyt lists locations in Le Vésinet, Manchester, Singapore, the USA and Canada, and notes the acquisition of Southern Cross Diagnostics in Australia in March 2026. » More on de.investing.com
Novacyt schedules general meeting for 30 June and announces investor presentation

Novacyt will hold its annual general meeting on 30 June 2026 at 11:00 CEST at the Hilton Paris Charles de Gaulle. CEO Lyn Rees and CFO Steve Gibson will deliver an investor presentation on the day of the meeting via the Investor Meet Company platform; the presentation will have automatic French captions. Investors can register for the webinar through the platform; the following users will automatically receive an invitation. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Novacyt has already paid €0.00998 in dividends. The last payout was in July 2022.

Financials

In the last quarter, Novacyt had revenue of €10.25M and net profit of -€16.57M

(EUR)	Dec 2025	YoY
Revenue	10.25M	-
Gross profit	3.53M	-
Net profit	-16.57M	-
EBITDA	-3.86M	-

Fundamentals

Metric	Value
Market capitalization	€35.85M
Number of shares	72.5M
52-week high/low	€1.04 - €0.29
Dividends	No
Beta	1.11
P/E ratio	-0.93
PEG ratio	-0.02
P/B ratio	1.28
P/S ratio	1.22

Company profile

Novacyt S.A. ist zusammen mit seinen Tochtergesellschaften in der Entwicklung, Herstellung, Auftragsentwicklung und Vermarktung von diagnostischen Produkten für Krebs- und Infektionskrankheiten in Großbritannien, dem übrigen Europa, den Vereinigten Staaten, dem asiatisch-pazifischen Raum, dem Nahen Osten und Afrika tätig. Das Unternehmen ist über Primer Design, Lab21 Products und IT-IS International tätig. Das Segment Primer Design entwickelt, produziert und vermarktet molekulare Echtzeit-qPCR-Testgeräte und Reagenzien für den Bereich Infektionskrankheiten. Das Segment Lab21 Products entwickelt, produziert und vertreibt eine Reihe von proteinbasierten In-vitro-Diagnostikprodukten (IVD) für Infektionskrankheiten. Das Segment IT-IS International entwickelt und fertigt PCR-Geräte für die Biowissenschaften und die Lebensmitteltestindustrie. Es beliefert Krankenhäuser und Unternehmen. Das Unternehmen wurde im Jahr 2006 gegründet und hat seinen Sitz in Vélizy-Villacoublay, Frankreich.